Mounjaro: a complete profile of tirzepatide, its benefits, drawbacks and dangers

Introduction

Mounjaro, whose active substance is tirzepatide, has become in just a few years one of the most talked-about medicines in diabetes and weight loss. Videos on TikTok, Instagram or YouTube sometimes present it as a quick, almost miraculous way to lose several kilos.

Its popularity echoes the craze around Ozempic, another medicine acting on the gut hormone system. The comparison is imperfect, though: Ozempic contains semaglutide, while Mounjaro contains tirzepatide. The two treatments have different indications, mechanisms and clinical data.

Tirzepatide is a genuine medicine, intended to be prescribed in specific medical situations. It is not a food supplement, not a cosmetic, and not a harmless injection to shed a few kilos before summer. In the European Union, Mounjaro is authorised for insufficiently controlled type 2 diabetes in adults, adolescents and children aged 10 and over. For weight management, it is authorised in adults with an initial BMI of at least 30 kg/m², or at least 27 kg/m² with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity (source 1).

Growing demand, social media exposure and purchases outside the pharmacy supply chain raise serious concerns. On 30 July 2026, the World Health Organization warned about GLP-1 agonist medicines being obtained outside authorised indications and medical settings, notably through online platforms and informal channels (source 2).

Disclaimer: this article provides general information. It does not replace a medical consultation. Any use of Mounjaro must be discussed with a doctor and monitored by a healthcare professional.

What is Mounjaro?

Natural Mounjaro” does not exist: it is a social media trend for homemade slimming drinks. Real Mounjaro is a prescription medicine (tirzepatide). These drinks are nowhere near as effective, even if their ingredients are healthy.

Mounjaro is the brand name of tirzepatide, an injectable medicine usually given once a week. It belongs to a particular class of molecules called dual GIP and GLP-1 receptor agonists.

Both hormones are naturally produced by the gut after meals. Among other things, they help to:

  • regulate blood sugar;
  • stimulate insulin secretion when blood sugar rises;
  • reduce glucose production by the liver;
  • slow down stomach emptying;
  • regulate hunger and satiety.

Tirzepatide mimics the action of these hormones, with an action long enough to allow a weekly injection. Its effect on appetite partly explains the weight loss seen in many patients (source 1).

Key terms

  • GLP-1: a gut hormone involved in blood sugar, satiety and digestion.
  • GIP: a gut hormone that contributes in particular to the insulin response after a meal.
  • Receptor agonist: a substance that reproduces or enhances the action of a natural hormone or messenger.
  • Blood sugar (glycaemia): the level of glucose, or sugar, in the blood.
  • BMI: body mass index, calculated from weight and height. It is an indicator, but it does not by itself sum up a person's health.

The story of Mounjaro

Tirzepatide was developed by Eli Lilly, building on research into gut hormones and the role of the digestive system in metabolism. Its development is part of a major shift in diabetes medicine: modern treatments no longer aim only to lower blood sugar, but also to act on weight and certain metabolic risk factors.

Mounjaro was first approved in the United States in May 2022 for the treatment of type 2 diabetes. In the European Union, its marketing authorisation was granted on 15 September 2022 (source 1).

Its public image then changed with the publication of clinical trials showing substantial weight loss in people with obesity or with overweight and related complications. Media coverage of these results turned tirzepatide into a highly sought-after product, including among people with no medical indication.

This has created a tension between two realities:

  1. Tirzepatide can be a useful therapeutic tool in properly selected patients.
  2. Cosmetic or unsupervised use exposes people to avoidable risks, and can make access harder for those who need the treatment.

When is Mounjaro used?

Type 2 diabetes

Mounjaro can be prescribed to adults and, according to the European indications in force on 20 September 2026, to children and adolescents aged 10 and over with insufficiently controlled type 2 diabetes (source 1). It can be used alone when metformin is unsuitable because of intolerance or contraindication, or in combination with other diabetes medicines (source 1).

The treatment can:

  • lower blood sugar;
  • improve some metabolic parameters;
  • reduce appetite;
  • promote weight loss in many patients.

The risk of hypoglycaemia is generally low when tirzepatide is used alone. However, it can increase when combined with insulin or with certain medicines called sulfonylureas. The doctor may then need to adjust the doses (source 1).

Overweight and obesity

Mounjaro can also be used for weight management in adults with an initial BMI of at least 30 kg/m², or a BMI from 27 to under 30 kg/m² with at least one weight-related condition, such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes (source 1).

It should be part of a broader strategy including:

  • a suitable diet;
  • physical activity adapted to the person's health;
  • medical support;
  • attention to sleep, stress and psychological factors;
  • long-term follow-up, because obesity is a chronic disease, not a mere lack of willpower.

The treatment is therefore not meant for anyone who simply wants to lose a few kilos. The World Health Organization recommends considering medicines of this family within structured medical care, particularly for adults living with obesity (source 3).

How does tirzepatide affect weight?

Weight loss relies on several complementary mechanisms.

Reduced appetite

Tirzepatide acts on brain regions involved in hunger and satiety. Some people feel hungry less often, feel full sooner or think about food less frequently.

Slower stomach emptying

The medicine can slow the passage of food from the stomach to the intestine, so the feeling of fullness can last longer. This mechanism also explains some digestive side effects, such as nausea, bloating and a heavy stomach (source 1).

Better glucose regulation

In people with diabetes, tirzepatide increases insulin secretion when blood sugar is high and reduces excessive glucose release by the liver. This helps control diabetes (source 1).

Reduced fat mass

Clinical trials indicate that the weight lost is mainly fat mass (source 1). However, any substantial weight loss can also come with a loss of muscle mass, especially if food intake is insufficient or if physical activity does not include strength training.

Loss of muscle mass is not specific to tirzepatide and cannot be called "harmful" in every case. It should rather be monitored, particularly when weight loss is rapid, nutritional intake is insufficient or physical activity is low.

What are the potential benefits?

Strong efficacy in some patients

Clinical studies have shown greater weight loss than with placebo in people with obesity or with overweight and related complications. According to the European Medicines Agency, in a 72-week trial more than 85% of participants on Mounjaro lost at least 5% of their body weight, compared with 35% in the placebo group (source 1).

These results do not mean everyone will lose the same amount. The response depends on:

  • the dose;
  • the length of treatment;
  • diet;
  • physical activity;
  • age;
  • medical history;
  • other medicines taken;
  • individual response to treatment.

Better diabetes control

In people with type 2 diabetes, Mounjaro can help lower glycated haemoglobin (HbA1c), an indicator of blood sugar balance over several weeks (source 1).

Associated metabolic benefits

Weight loss and improved blood sugar can come with improvements in some risk factors, such as blood pressure or blood lipids. These benefits should not, however, be read as a guarantee against all cardiovascular disease (source 1).

Weekly administration

One injection a week can be simpler for some patients than daily doses. This convenience does not replace regular medical follow-up.

The most common side effects

Digestive side effects are the most frequently reported. They often appear at the start of treatment or after a dose increase.

The main ones are:

  • nausea;
  • diarrhoea;
  • vomiting;
  • abdominal pain;
  • constipation;
  • decreased appetite;
  • indigestion;
  • bloating;
  • reflux or a feeling of slow digestion.

These symptoms are often mild to moderate, but they can become troublesome or lead to dehydration. The European Medicines Agency notes that digestive side effects are generally more frequent when the dose is being increased (source 1).

A treatment one person tolerates well may be hard for another. Never copy a relative's dose or schedule.

Used without supervision or medical follow-up, the treatment can lead to sometimes serious digestive complications, including severe nausea and vomiting, dehydration or, more rarely, inflammation of the pancreas. Gastroparesis — an abnormal slowing of stomach emptying — has also been reported with this family of medicines, but it should not be presented as a frequent complication or as a systematic "stomach paralysis".

Possible dangers and complications

Dehydration and kidney damage

Repeated vomiting or diarrhoea can lead to dehydration. This can lower blood pressure and worsen pre-existing kidney failure.

Particular care is needed for:

  • older people;
  • people with kidney disease;
  • patients taking diuretics;
  • people unable to drink enough;
  • patients with persistent vomiting.

Acute pancreatitis

Acute pancreatitis is a sudden inflammation of the pancreas. It remains uncommon, but it is a potentially serious complication.

Seek medical help promptly for severe, persistent pain in the upper abdomen that may spread to the back, especially with vomiting. The European product information lists acute pancreatitis as an uncommon side effect; if it is suspected, tirzepatide must be stopped and must not be restarted if the diagnosis is confirmed (source 4).

Gallbladder problems

Rapid weight loss can promote gallstones. Gallbladder disorders have also been observed with medicines of this family.

Severe pain under the right ribs, fever, yellowing of the skin or eyes, or persistent vomiting call for prompt medical advice.

Hypoglycaemia

The risk is mainly a concern when Mounjaro is combined with insulin or a sulfonylurea. Possible symptoms include:

  • sweating;
  • trembling;
  • palpitations;
  • intense hunger;
  • dizziness;
  • confusion;
  • difficulty concentrating;
  • loss of consciousness in severe cases.

The doctor may adjust the associated treatment to limit this risk.

Allergic reactions

Serious allergic reactions, although rare, can occur. Swelling of the face, lips or throat, difficulty breathing, a widespread rash or feeling faint require emergency care.

Risks with anaesthesia

Because Mounjaro can slow stomach emptying, it is important to mention it before anaesthesia or any procedure requiring sedation. The care team then assesses individually the risk of residual stomach contents and the precautions to take; international recommendations do not necessarily call for stopping the treatment in all patients (source 8).

Anyone on treatment should inform the anaesthetist, the surgeon and the other professionals involved.

The theoretical risk of thyroid tumours

Animal data on tirzepatide showed an increase in certain thyroid C-cell tumours in rats. The relevance of this finding in humans is not established, but it justifies particular precautions.

In the United States, tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (source 5). Rules may differ by country and by the applicable leaflet. Anyone concerned should discuss it with their doctor before treatment.

Contraindications and situations requiring medical advice

Mounjaro should not be used without a medical assessment. The healthcare professional needs to know in particular about:

  • any history of pancreatitis;
  • significant digestive diseases;
  • kidney or liver disease;
  • any history of gallstones;
  • diabetes treatments;
  • any history of eating disorders;
  • planned surgery;
  • pregnancy or plans for pregnancy;
  • breastfeeding;
  • a personal or family history of certain thyroid diseases.

Women who are pregnant or planning a pregnancy should seek medical advice. Tirzepatide is not recommended during pregnancy or in women of childbearing potential not using contraception. The European leaflet recommends stopping it at least one month before a planned pregnancy (source 4).

Mounjaro for cosmetic weight loss: why is it a concern?

The myth of the miracle drug

On social media, the medicine is sometimes presented as a simple, fast and universal solution. That picture leaves out several essentials:

  • side effects;
  • the need for gradual dose increases;
  • contraindications;
  • interactions with other treatments;
  • possible weight regain after stopping;
  • the need for long-term follow-up.

The term "miracle drug" is particularly misleading. Mounjaro does not remove the causes of obesity, does not suit everyone and does not guarantee lasting weight loss after it is stopped. In the SURMOUNT-4 trial, participants switched from tirzepatide to placebo after an initial treatment period regained on average 14% of their body weight between weeks 36 and 88, while those who continued treatment lost a further 5.5% on average (source 9).

Use by people with no indication

Some people seek to lose a few kilos without having obesity or any weight-related complication. In that situation, the balance between expected benefits and risks can be unfavourable.

Taking a powerful medicine to change one's figure without a medical indication exposes people to side effects that may be out of proportion with the benefit sought. It can also reinforce social pressure around thinness and normalise the idea that an injectable treatment is needed to achieve a certain look.

Pressure on supply

Higher demand can make access to some treatments of this family harder when supply cannot keep up. That said, whether shortages exist and how severe they are varies by medicine, strength, country and period, so it is better to check with the competent authorities than to speak vaguely of "regular shortages". In Belgium, the FAMHP (AFMPS) has reported availability restrictions for some GLP-1 analogues and reminds the public that these medicines are dispensed on prescription in an authorised pharmacy (sources 6 and 10).

Those affected are not only people with "severe obesity": the European indication for Mounjaro also covers some overweight adults with a weight-related condition, as well as patients with type 2 diabetes who meet the medical criteria.

The danger of online purchases and falsified products

Buying through social networks, forums, unauthorised foreign websites or private individuals carries several risks:

  • product not containing the right active substance;
  • wrong dose;
  • storage at the wrong temperature;
  • contamination;
  • non-sterile injection device;
  • no traceability;
  • no reliable leaflet;
  • no way to check the expiry date;
  • no follow-up in case of side effects.

The WHO has reported falsified GLP-1 agonist products, notably in a context of high demand and limited access to some products (source 7). This alert does not mean that every product bought in a pharmacy is affected, but it is a good reason never to use a medicine obtained through an unauthorised channel.

Falsified products may contain too little, too much or an unknown amount of active substance. They may also contain another dangerous product.

Never order Mounjaro from a private individual, on social media or from a website offering it without a prescription. If in doubt about a pen or a box, do not use it and ask a pharmacist.

What happens after stopping?

Mounjaro does not necessarily cure the cause of overweight or obesity. Its effect on appetite and satiety gradually wears off after stopping, so some people regain part of the weight lost (source 9).

That does not make the treatment useless. Rather, it is a reminder that obesity care needs to be planned for the long term. Stopping, continuing or changing the dose should be discussed with the doctor.

Stopping the treatment on your own is not advised, particularly for people with diabetes, as blood sugar may rise.

Practical tips for safer use

When a doctor prescribes Mounjaro, a few precautions can reduce the risks:

  1. Use only the prescribed device, at the prescribed dose.
  2. Do not increase the dose yourself, even if weight loss seems insufficient.
  3. Never share an injection pen, even with a new needle.
  4. Follow the storage conditions in the leaflet.
  5. Drink enough, especially with nausea, diarrhoea or vomiting.
  6. Inform healthcare professionals before anaesthesia or a procedure.
  7. Report any unusual side effect to your doctor or pharmacist.
  8. Do not combine Mounjaro with another weight-loss medicine or GLP-1 agonist without medical advice.
  9. Keep up adequate protein intake and suitable activity to limit muscle loss.
  10. Seek help quickly for severe abdominal pain, persistent vomiting, dehydration, an allergic reaction or symptoms of hypoglycaemia.

Current state of scientific knowledge

The available data show that tirzepatide can effectively improve blood sugar and promote weight loss in selected patients. Its benefit-risk balance is considered favourable when it is used within its indications, with appropriate prescription and follow-up (sources 1 and 2).

Several questions nonetheless remain important:

  • the effects of very long-term use in diverse populations;
  • weight regain after stopping;
  • changes in muscle mass;
  • the consequences of use in people without obesity;
  • the impact of combinations with other treatments;
  • the risks of self-medication;
  • the quality of preparations or products sold outside official channels.

The WHO stresses that these treatments can be a useful option in obesity care, but that they replace neither prevention, nor nutritional support, nor physical activity, nor a sustainable organisation of care (source 3).

Conclusion

Mounjaro is a medicine that can bring substantial benefits in type 2 diabetes and in some cases of overweight or obesity. Its effect on blood sugar and weight explains the enthusiasm it generates.

But its media success also encourages inappropriate use: chasing rapid weight loss, prescriptions without adequate assessment, shared pens, self-directed dose increases or products bought online. These practices expose people to side effects, interactions, digestive or metabolic complications and, with falsified products, risks that are impossible to predict.

Mounjaro should therefore not be seen as a cosmetic product or a miracle drug. It is a prescription treatment whose value depends on each patient's medical profile. The safest rule remains simple: use it only on medical advice, get it from an authorised pharmacy and have regular follow-up.

Sources

  1. European Medicines Agency, "Mounjaro — European Public Assessment Report", marketing authorisation granted on 15 September 2022; product information consulted on 20 September 2026.

  2. World Health Organization, "Statement on the safe and appropriate use of GLP-1 receptor agonists", 30 July 2026.

  3. World Health Organization, "WHO issues global guideline on the use of GLP-1 medicines for the treatment of obesity in adults", 1 December 2025.

  4. European Medicines Agency, "Mounjaro — Product information", consulted on 20 September 2026.

  5. U.S. Food and Drug Administration, "Mounjaro — Prescribing Information", 2025.

  6. Federal Agency for Medicines and Health Products (FAMHP/AFMPS), "L'AFMPS met en garde contre la vente illégale d'analogues du GLP-1 sur les réseaux sociaux" (in French), 25 August 2025; page consulted on 20 September 2026.

  7. World Health Organization, "Shortages impacting access to glucagon-like peptide 1 receptor agonist products", 29 January 2024.

  8. American Society of Anesthesiologists and partner organisations, "Most Patients Can Continue Diabetes, Weight Loss GLP-1 Drugs Before Surgery", 29 October 2024; page consulted on 20 September 2026.

  9. Aronne L. J. et al., "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial", JAMA, 2024.

  10. Federal Agency for Medicines and Health Products (FAMHP/AFMPS), "Disponibilité restreinte des analogues du GLP-1 : extension de la restriction de prescription" (in French), on availability restrictions in Belgium; page consulted on 20 September 2026.

Further sources

a. World Health Organization, "Medical Product Alert: falsified Ozempic", 19 June 2024.

b. U.S. Food and Drug Administration, "Mounjaro — Information for healthcare professionals", page consulted on 20 September 2026.

← Back to articles